Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema

202321 citationsJournal Articlegreen Open Access

Authors

David W. Hutton · University of Michigan

Adam R. Glassman · Jaeb Center for Health Research

Danni Liu · Jaeb Center for Health Research

Jennifer K. Sun · Joslin Diabetes Center

Abstract

Variability in individual needs will influence clinician and patient decisions about how to treat specific eyes with DME. While the bevacizumab-first group costs still averaged approximately $14 000 over 2 years, this approach, as used in this study, may confer substantial cost savings on a societal level without sacrificing visual acuity gains over 2 years compared with aflibercept monotherapy.

Topics & Keywords

Retinal Diseases and Treatments Retinal Imaging and Analysis Retinal and Optic Conditions

Publication Details

Published in: JAMA Ophthalmology

Volume 141, Issue 3, pp. 268-268

DOI: 10.1001/jamaophthalmol.2022.6142

Field-Weighted Citation Impact: 5.82

Command Palette

Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema

Authors

Abstract

Topics & Keywords

Publication Details